SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (11428)8/20/1999 3:55:00 PM
From: Pseudo Biologist  Respond to of 17367
 
Why didn't Xoma go up on the same non mention?

Because Xoma does not have a phase III trial going on, EXPLICITLY, for an antibiotic used as such. Daptomycin is a "large" small molecule that looks more like your typical antibiotic, although it is in a different chemical and mechanistic class from everything else already out there. It is not a protein.

Either way, I am not too impressed by CBST at *this* valuation. This almost surely means it will double shortly -g-

PB



To: aknahow who wrote (11428)8/20/1999 4:55:00 PM
From: Bluegreen  Read Replies (2) | Respond to of 17367
 
George, keep in mind the possibility of Xoma being buyout bait. If you were a big pharma why make a single deal involving Mycoprex if you could buy the whole enchilada on the cheap? AND you wouldn't have to worry about the enchilada getting into trouble with Bloomberg reporters and having their employees and stockholders shall we say upset? Happy employees and stockholders with stable stock price goes a long way in getting drugs approved.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News